TW200611910A - Interferon-alpha polypeptides and conjugates - Google Patents
Interferon-alpha polypeptides and conjugatesInfo
- Publication number
- TW200611910A TW200611910A TW094116107A TW94116107A TW200611910A TW 200611910 A TW200611910 A TW 200611910A TW 094116107 A TW094116107 A TW 094116107A TW 94116107 A TW94116107 A TW 94116107A TW 200611910 A TW200611910 A TW 200611910A
- Authority
- TW
- Taiwan
- Prior art keywords
- conjugates
- polypeptides
- nucleic acids
- interferon
- alpha polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57250404P | 2004-05-19 | 2004-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200611910A true TW200611910A (en) | 2006-04-16 |
Family
ID=35428915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094116107A TW200611910A (en) | 2004-05-19 | 2005-05-18 | Interferon-alpha polypeptides and conjugates |
Country Status (14)
Country | Link |
---|---|
US (9) | US7318918B2 (zh) |
EP (1) | EP1753779A2 (zh) |
JP (1) | JP2008507298A (zh) |
CN (1) | CN101115769A (zh) |
AR (1) | AR049177A1 (zh) |
AU (1) | AU2005245918A1 (zh) |
BR (1) | BRPI0511196A (zh) |
CA (1) | CA2566247A1 (zh) |
IL (1) | IL178470A0 (zh) |
MX (1) | MXPA06013412A (zh) |
NO (1) | NO20065084L (zh) |
RU (1) | RU2006145020A (zh) |
TW (1) | TW200611910A (zh) |
WO (1) | WO2005113592A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI565714B (zh) * | 2011-06-02 | 2017-01-11 | 韓美科學股份有限公司 | 非肽基聚合物-胰島素集合體及其製造方法 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU774306B2 (en) * | 1999-01-05 | 2004-06-24 | Trustees Of Boston University | Improved nucleic acid cloning |
US20040005673A1 (en) | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
US20030017552A1 (en) * | 2000-07-21 | 2003-01-23 | Jarrell Kevin A. | Modular vector systems |
US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
EP1759521B1 (en) * | 2004-05-12 | 2016-06-29 | Synchronoss Technologies, Inc. | Advanced contact identification system |
ATE540110T1 (de) | 2004-11-11 | 2012-01-15 | Modular Genetics Inc | Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt |
CA2597317C (en) * | 2005-03-09 | 2018-01-02 | Guangwen Wei | Uses of recombinant super-compound interferons |
MX2007014524A (es) | 2005-05-18 | 2008-02-07 | Maxygen Inc | Polipeptidos desarrollados de interferon-alfa. |
AR078117A1 (es) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
US20080014616A1 (en) * | 2006-07-11 | 2008-01-17 | Kevin Jarrell | Methods of introducing targeted diversity into nucleic acid molecules |
JPWO2008013082A1 (ja) * | 2006-07-25 | 2009-12-17 | 株式会社ガルファーマ | ガレクチン9−ポリマーコンジュゲート |
US7808342B2 (en) * | 2006-10-02 | 2010-10-05 | Skyworks Solutions, Inc. | Harmonic phase tuning filter for RF switches |
WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
WO2009006579A1 (en) * | 2007-07-05 | 2009-01-08 | Pharmaessentia Corp. | Peptide-polymer conjugates |
EP2195338B1 (en) * | 2007-10-01 | 2013-12-25 | Pharmaessentia Corp. | N-terminal modified interferon-alpha |
KR20100103595A (ko) * | 2008-01-18 | 2010-09-27 | 에프. 호프만-라 로슈 아게 | 비-글라이코실화된 단백질의 정제 |
US7954022B2 (en) * | 2008-01-30 | 2011-05-31 | Alcatel-Lucent Usa Inc. | Apparatus and method for controlling dynamic modification of a scan path |
KR20110086705A (ko) * | 2008-11-17 | 2011-07-29 | 제넨테크, 인크. | 생리학적 조건 하에 거대분자의 응집을 감소시키는 방법 및 제제 |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
WO2013003555A1 (en) | 2011-06-28 | 2013-01-03 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
CN102358897B (zh) * | 2011-10-31 | 2013-02-13 | 北京三元基因工程有限公司 | 重组人寡腺苷酸合成酶-1的制备方法 |
US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
DK3006045T3 (en) * | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
RU2650755C1 (ru) * | 2017-05-24 | 2018-04-17 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С |
EP4093755A1 (en) * | 2020-01-24 | 2022-11-30 | Alkermes Pharma Ireland Limited | Methods of purification |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
ES8302778A1 (es) | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
JPS60152058A (ja) * | 1984-01-20 | 1985-08-10 | Toshiba Corp | 半導体記憶装置 |
EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
US4695626A (en) * | 1986-07-29 | 1987-09-22 | Pfizer Inc. | 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
CA2094275C (en) | 1990-10-17 | 2003-06-03 | Lawrence M. Blatt | Methods and compositions for the treatment of cell proliferation disorders |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
DK0741577T3 (da) | 1994-03-07 | 2003-02-17 | Imperial College | Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
WO2000042175A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
WO2001087925A2 (en) | 2000-05-16 | 2001-11-22 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
WO2000052153A2 (en) | 1999-03-02 | 2000-09-08 | Maxygen, Inc. | Method to identify ligands for orphan receptors |
MXPA01011845A (es) | 1999-05-19 | 2002-06-21 | Lexigen Pharm Corp | Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc. |
WO2001025438A2 (en) * | 1999-10-07 | 2001-04-12 | Maxygen, Inc. | Ifn-alpha homologues |
US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
JP2003513681A (ja) * | 1999-11-12 | 2003-04-15 | マキシゲン・ホールディングス・リミテッド | インターフェロンガンマ・コンジュゲート |
WO2002044197A2 (en) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
KR100459105B1 (ko) | 2001-02-15 | 2004-12-03 | 선바이오(주) | 변형된 인터페론-알파 2a 및 2b, 그리고 이들과 PEG유도체와의 배합체 |
EP1562634B1 (en) | 2002-11-15 | 2006-08-23 | F. Hoffmann-La Roche Ag | Positional isomers of pegylated interferon alpha 2a |
JP2006506097A (ja) * | 2002-11-18 | 2006-02-23 | マキシジェン, インコーポレイテッド | インターフェロン−αのポリペプチドおよび結合体 |
-
2005
- 2005-05-18 EP EP05751765A patent/EP1753779A2/en not_active Withdrawn
- 2005-05-18 RU RU2006145020/04A patent/RU2006145020A/ru unknown
- 2005-05-18 US US11/132,722 patent/US7318918B2/en not_active Expired - Fee Related
- 2005-05-18 JP JP2007527427A patent/JP2008507298A/ja active Pending
- 2005-05-18 BR BRPI0511196-0A patent/BRPI0511196A/pt not_active Application Discontinuation
- 2005-05-18 TW TW094116107A patent/TW200611910A/zh unknown
- 2005-05-18 CA CA002566247A patent/CA2566247A1/en not_active Abandoned
- 2005-05-18 AU AU2005245918A patent/AU2005245918A1/en not_active Abandoned
- 2005-05-18 CN CNA2005800241473A patent/CN101115769A/zh active Pending
- 2005-05-18 MX MXPA06013412A patent/MXPA06013412A/es unknown
- 2005-05-18 WO PCT/US2005/017471 patent/WO2005113592A2/en active Application Filing
- 2005-05-19 AR ARP050102059A patent/AR049177A1/es unknown
-
2006
- 2006-09-13 US US11/531,557 patent/US7531324B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,570 patent/US20070020734A1/en not_active Abandoned
- 2006-09-13 US US11/531,531 patent/US7531630B2/en not_active Expired - Fee Related
- 2006-09-14 US US11/532,024 patent/US20070225204A1/en not_active Abandoned
- 2006-09-14 US US11/532,045 patent/US20070225205A1/en not_active Abandoned
- 2006-10-05 IL IL178470A patent/IL178470A0/en unknown
- 2006-11-03 NO NO20065084A patent/NO20065084L/no unknown
-
2007
- 2007-05-04 US US11/744,424 patent/US7541436B2/en not_active Expired - Fee Related
- 2007-08-14 US US11/838,730 patent/US7541163B2/en not_active Expired - Fee Related
- 2007-08-15 US US11/839,493 patent/US7537755B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI565714B (zh) * | 2011-06-02 | 2017-01-11 | 韓美科學股份有限公司 | 非肽基聚合物-胰島素集合體及其製造方法 |
US9944688B2 (en) | 2011-06-02 | 2018-04-17 | Hanmi Science Co., Ltd. | Non-peptidyl polymer-insulin multimer and method for producing the same |
Also Published As
Publication number | Publication date |
---|---|
JP2008507298A (ja) | 2008-03-13 |
US7531630B2 (en) | 2009-05-12 |
US20070225204A1 (en) | 2007-09-27 |
US20070225205A1 (en) | 2007-09-27 |
US20070020235A1 (en) | 2007-01-25 |
CA2566247A1 (en) | 2005-12-01 |
US7531324B2 (en) | 2009-05-12 |
US7541436B2 (en) | 2009-06-02 |
AR049177A1 (es) | 2006-07-05 |
US20080171363A1 (en) | 2008-07-17 |
MXPA06013412A (es) | 2007-01-23 |
WO2005113592A3 (en) | 2006-04-06 |
US20070025966A1 (en) | 2007-02-01 |
BRPI0511196A (pt) | 2007-12-04 |
US7537755B2 (en) | 2009-05-26 |
US20080031853A1 (en) | 2008-02-07 |
IL178470A0 (en) | 2007-02-11 |
US20050266465A1 (en) | 2005-12-01 |
US20070020734A1 (en) | 2007-01-25 |
NO20065084L (no) | 2006-12-01 |
RU2006145020A (ru) | 2008-06-27 |
EP1753779A2 (en) | 2007-02-21 |
US7541163B2 (en) | 2009-06-02 |
WO2005113592A2 (en) | 2005-12-01 |
CN101115769A (zh) | 2008-01-30 |
US7318918B2 (en) | 2008-01-15 |
AU2005245918A1 (en) | 2005-12-01 |
US20080076710A1 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200611910A (en) | Interferon-alpha polypeptides and conjugates | |
WO2006083276A3 (en) | Interferon-alpha polypeptides and conjugates | |
WO2007044083A3 (en) | Evolved interferon-alpha polypeptides | |
WO2004046365A3 (en) | Interferon-alpha polypeptides and conjugates | |
WO2006017538A3 (en) | Hk1-binding proteins | |
EP1649006A4 (en) | EXO-SPECIFIC AMYLASE POLYPEPTIDES, THESE POLYPEPTIDE-CODING NUCLEIC ACIDS, AND USES THEREOF | |
IL190796A (en) | Composition containing nucleic acid encoded by anti-osteoclastogenic protein | |
WO2005121331A8 (en) | Truncated galnact2 polypeptides and nucleic acids | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
WO2004078120A3 (en) | Collagen compositions and biomaterials | |
EP1709195A4 (en) | CELLULAR TRANSFECTION FORMULATIONS OF SMALL INTERFERING RNA, COMPOSITIONS THEREFOR, AND METHODS OF PRODUCTION AND USE | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
TNSN07157A1 (en) | Melanocortin receptor binding mimetibodies, compositions, methods and uses | |
IL157335A0 (en) | Lentiviral packaging constructs | |
AU3281902A (en) | Methods for the production of multimeric proteins, and related compositions | |
WO2004007664A3 (en) | Nucleic acid vectors | |
AU153659S (en) | Container | |
WO2001049721A3 (en) | Bacterial genes and proteins that are essential for cell viability and their uses | |
PL1677818T3 (pl) | Stabilne kompozycje wodne zawierające G-CSF | |
EP1828237A4 (en) | HUMAN CANCER SUPPRESSOR GENE, PROTEIN ENCODED THEREIN, EXPRESSION VECTOR CONTAINING THE GENE, AND CELL TRANSFORMED BY THE VECTOR | |
AU2003259750A8 (en) | Methods and compositions for targeting secretory lysosomes | |
MXPA03002581A (es) | Composicion a base de copolicarbonatos. | |
EP1639109A4 (en) | DNA VECTORS | |
TW200504218A (en) | Methods for preventing gluconoylation of proteins | |
WO2003095484A3 (en) | Polypeptides increasing p53 expression |